Clear skin supplement and medicinal composition for acne

Abstract

There is disclosed a clear skin supplement/medicinal component for acne comprising: an orally administered dosage comprising of between about 3000-9000 mg of the Chinese medicinal composition comprising by ratio: around 3.8-7.6% of each of Prunus persica, Carthamus tinctorius, Angelica dahurica, Gleditsia sinensis, Viola yedoensis, Paeonia suffruticosa and gardenia jasminoides; around 5.7-7.6% of each of Oldenlandia diffusa and Scutellaria baicalensis; around 3.8-5.7% of Salvia miltiorrhiza; around 2.5-5.7% of Phellodendron amurense; around 2.5-7.6% of Gentiana scabra; and around 0-7.6% of each of Taraxacum mongolicum and any one of Lonicera japonica/Rhizoma Coptidas/Sophora flavescens.

Claims

1. A clear skin supplement/medicinal component for acne comprising: an orally administered dosage comprising of between about 3000-9000 mg of a Chinese medicinal composition, comprising by ratio: around 3.8-7.6% of each of Prunus persica, Carthamus tinctorius, Angelica dahurica, Gleditsia sinensis, Viola yedoensis, Paeonia sujfruticosa, and Gardenia jasminoides; around 5.7-7.6% of each of Oldenlandia diffusa and Scutellaria baicalensis; around 3.8-5.7% of Salvia miltiorrhiza; around 2.5 5.7% of Phellodendron amurense; around 2.5-7.6% of Gentiana scabra; and around 0-7.6% of each of Taraxacum mongolicum and any one of Lonicera japonica, Rhizoma coptidas, and Sophora flavescens.

2. The supplement according to claim 1, wherein the Chinese medicinal composition also comprises by ratio between 0-3.8% of each of Zingiber officinale and Glycyrrhiza uralensis; and 0-5.7% of Angelica polymorpha.

3. A method of administering a supplement in accordance with claim 1, wherein the supplement is provided in tablet form and the tablet is ingested by the user.

4. A method or forming a clear skin supplement/medicinal component for treating acne comprising method or forming a supplement in accordance with claim 1, comprising: loading the raw materials into an extractor; adding water to the extractor, up to ten times the weight of the combined raw materials; mixing the mixture of raw materials and water within the extractor; soaking the mixture for a predetermined period of time; boiling the mixture at around 100° C. and retaining the mixture at around 100° C. temperature for approximately one hour; extracting the remaining liquid into a dedicated storage tank; refilling the extractor with water up to ten times the weight of the combined raw materials and repeating the mixing, soaking, boiling and extracting steps; feeding the extracted liquid to a concentrator where the liquid is maintained at 40-60° C. for approximately two hours until the water content is reduced to around 35-60% and the liquid has a consistency of a paste; removing the paste from the concentrator refrigerating the paste; adding a carrier into a granulator; spraying the granulator with the concentrated paste at a temperature of around 55-65° C. to form granules; and mixing the granules with a further excipient to form tablets.

Description

DETAILED DESCRIPTION

(1) The present disclosure will be described below in further detail with reference to various examples.

(2) In some examples, the clear skin supplement is provided in tablet or capsule form for oral ingestion by an individual having a skin inflammation condition, such as acne. The tablet may be uncoated however in some instances, a coating, such as an enteric coating, may be applied to the tablet for controlling the delivery and ingestion of the active ingredients contained therein. However, in alternative embodiments, the present disclosure may present the ingredients in a powdered or raw form whereby they may be ingested orally or applied topically to the surface of the skin experiencing inflammation, to address such inflammation.

(3) The primary ingredients of the present disclosure are listed below in Table 1, together with the part of the plant that the ingredient is taken from.

(4) Each of the above ingredients have various properties in accordance with Chinese medicine, to deal with a variety of conditions associated with the skin. For example, Prunus Persica, Carthamus tinctorius and Salvia miltiorrhiza have been known to increase blood circulation and to treat blood stagnation. Hedyotis diffusa is also known as being useful in reducing heat and toxicity levels and breaking down blood stagnation, as have Viola Yedoensis, Taraxacum Mongolicum, Lonicera Japonica, Phellodendron Amurense, Paeonia Suffruticosa and Gardenia Florida. Angelica Dahurica and Gleditsia Sinensis are also known in their use of reducing swellings and abscesses on the skin.

(5) Zingiber officinale, Angelica polymorpha, and Glycyrrhiza uralensis are each secondary ingredient and are known for their ability to work with other ingredients to enhance their efficacy.

(6) TABLE-US-00001 TABLE 1 In relation to Lonicera Japonica, this ingredient may be replaced with more readily available ingredients such as Rhizoma Coptidis or Sophora Flavescens, depending upon availability. In this embodiment, potato starch is used as an excipient or carrier to bind the ingredients together in tablet form. AHN Plant Part Primus persica Kernel Carthamus tinctorius Flower Salvia miltiorrhiza Root Hedyotis diffusa, Herba Plant Angelica dahurica Root Gleditsia sinensis, Spina Spine Viola yedoensis, Herba Plant Taraxacum mongolicum, Herba Plant Lonicera japonica Flower Phellodendron amurense Bark Paeonia suffruticosa Root Bark gardenia florida Fruit Gentiana scabra Root Scutellaria baicalensis Root Zingiber officinale Rhizome Angelica polymorpha Root Glycyrrhiza uralensis Root Starch-Potato

(7) Table 2 depicts the proportions of each ingredient per 750 mg tablet.

(8) TABLE-US-00002 TABLE 2 % per 750 AHN Type mg Tablet Prunus persica Active/primary 2-3 Carthamus tinctorius Active/primary 2-3 Salvia miltiorrhiza Active/primary 2-3 Oldenlandia diffusa, Herba Active/primary 4-5 Angelica dahurica Active/primary 4-5 Gleditsia sinensis, Spina Active/primary 4-5 Viola yedoensis, Herba Active/primary 4-5 Taraxacum mongolicum, Herba Active/primary 4-5 Lonicera japonica Active/secondary 4-5 Phellodendron amurense Active/primary 2.5-3.5 Paeonia suffruticosa Active/primary 2-3 gardenia jasminoides Active/primary 1.5-2.5 Gentiana scabra Active/primary 2-3 Scutellaria baicalensis Active/primary 2-3 Zingiber officinale Active/secondary 0-2 Angelica polymorpha Active/secondary 0-2 Glycyrrhiza uralensis Active/secondary .sup. 0-1.5 Starch-Potato Excipient 48-50

(9) In order to prepare the tablets, each of the above raw materials are loaded into an extractor and water is added, up to ten times the weight of the combined raw material. The proportions of materials that make up the raw mixture is depicted in Table 3. The mixture is then allowed to soak for an hour before it is brought to boil at 100° C. The mixture is retained at this temperature for approximately one hour after which the liquid is extracted to a dedicated storage tank and the extractor is refilled with water in accordance with the above volume and the extraction process is repeated.

(10) TABLE-US-00003 TABLE 3 Raw Range of Equivalent Prescrip- percentage AHN Qty (mg) tion (g) by ratio (%) Prunus persica 107 9 3.8-7.6 Carthamus tinctorius 107 9 3.8-7.6 Salvia miltiorrhiza 107 9 3.8-5.7 Oldenlandia diffusa, Herba 146 12 5.7-7.6 Angelica dahurica 146 12 3.8-7.6 Gleditsia sinensis, Spina 146 12 3.8-7.6 Viola yedoensis, Herba 146 12 3.8-7.6 Taraxacum mongolicum, Herba 146 12 .sup. 0-7.6 Lonicera japonica 146 12 .sup. 0-7.6 Phellodendron amurense 107 9 2.5-5.7 Paeonia suffruticosa 107 9 3.8-7.6 gardenia jasminoides 71 6 3.8-7.6 Gentiana scabra 107 9 2.5-7.6 Scutellaria baicalensis 107 9 5.7-7.6 Zingiber officinale 71 6 .sup. 0-3.8 Angelica polymorpha 71 6 .sup. 0-5.7 Glycyrrhiza uralensis 47 4 .sup. 0-3.8

(11) The extracted liquid is then fed to a concentrator where the liquid is maintained at 40-60% for two hours until the water content is reduced to around 35-60% and the liquid takes the consistency of a paste. This concentrated paste is then refrigerated.

(12) The carrier, in this embodiment, potato starch is then added into a granulator and the concentrated paste is sprayed into the granulator where the temperature is set at around 55-65° C. Analysis is able to be performed on the granules produced in this process for quality control purposes, after which the granules are mixed with a further excipient, such as magnesium stearate then to forming the tablets. The tablets are then packaged in bottles for distribution.

(13) The composition of the ingredients of the present disclosure is determined based on the knowledge that acne is largely caused by heat, blood stagnation, toxicity and inflammation in the skin. The above referenced primary ingredients have been selected to address each of these issues to reduce inflammation and increase circulation and blood flow and maintaining a health skin temperature that avoids toxin build-up.

(14) The tablets of the present disclosure may be recommended to a patient only after an initial consultation with a specialist. In some instances, it may be required that the percentage of the ingredients be increased to address specific issues identified during the consultation process. However, it is also envisaged that the tablets may be provided in retail outlets and the like for purchase without initial consultation.

(15) Throughout the specification and claims the word “comprise” and its derivatives are intended to have an inclusive rather than exclusive meaning unless the contrary is expressly stated or the context requires otherwise. That is, the word “comprise” and its derivatives will be taken to indicate the inclusion of not only the listed components, steps or features that it directly references, but also other components, steps or features not specifically listed, unless the contrary is expressly stated or the context requires otherwise.

(16) It will be appreciated by those skilled in the art that many modifications and variations may be made to the methods of the disclosure described herein without departing from the spirit and scope of the disclosure.